Your browser is no longer supported. Please, upgrade your browser.
Settings
RDHL [NASD]
RedHill Biopharma Ltd.
Index- P/E- EPS (ttm)-1.78 Insider Own0.29% Shs Outstand37.29M Perf Week-17.58%
Market Cap311.87M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float34.99M Perf Month-5.21%
Income-63.50M PEG- EPS next Q-0.24 Inst Own21.40% Short Float6.88% Perf Quarter-11.22%
Sales44.50M P/S7.01 EPS this Y15.10% Inst Trans7.74% Short Ratio4.07 Perf Half Y-1.14%
Book/sh0.77 P/B10.17 EPS next Y67.80% ROA-46.00% Target Price- Perf Year65.54%
Cash/sh0.87 P/C8.96 EPS next 5Y- ROE-152.20% 52W Range3.26 - 11.52 Perf YTD-3.09%
Dividend- P/FCF- EPS past 5Y-2.90% ROI-67.70% 52W High-32.03% Beta1.59
Dividend %- Quick Ratio1.60 Sales past 5Y-2.20% Gross Margin41.00% 52W Low140.03% ATR0.88
Employees155 Current Ratio1.80 Sales Q/Q1394.90% Oper. Margin- RSI (14)39.23 Volatility9.42% 8.32%
OptionableYes Debt/Eq2.99 EPS Q/Q-44.20% Profit Margin- Rel Volume1.08 Prev Close7.50
ShortableYes LT Debt/Eq2.94 Earnings- Payout- Avg Volume591.46K Price7.83
Recom1.60 SMA20-17.56% SMA50-11.06% SMA200-6.70% Volume640,456 Change4.40%
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Mar-05-21 07:00AM  
Mar-04-21 12:10PM  
Mar-02-21 09:06AM  
08:23AM  
Mar-01-21 04:53PM  
Feb-23-21 08:07AM  
07:33AM  
07:13AM  
07:03AM  
Feb-18-21 01:00PM  
07:00AM  
Feb-17-21 07:00AM  
Feb-11-21 06:55AM  
Feb-09-21 07:00AM  
Jan-29-21 07:45AM  
07:26AM  
07:00AM  
Jan-28-21 09:03AM  
08:02AM  
07:27AM  
Jan-26-21 06:20AM  
Jan-14-21 02:13PM  
Jan-12-21 12:56PM  
08:51AM  
Jan-11-21 04:35PM  
07:00AM  
07:00AM  
Jan-08-21 02:11PM  
Jan-07-21 09:28AM  
Jan-06-21 07:00AM  
Jan-04-21 09:41AM  
Dec-31-20 09:38AM  
09:30AM  
Dec-28-20 11:28AM  
Dec-22-20 07:00AM  
Dec-15-20 11:42AM  
09:30AM  
Dec-14-20 08:00AM  
Dec-07-20 07:00AM  
Nov-29-20 09:45PM  
Nov-27-20 04:53PM  
11:32AM  
Nov-25-20 12:39PM  
10:36AM  
Nov-24-20 06:00PM  
Nov-23-20 09:00AM  
08:00AM  
Nov-20-20 08:00AM  
Nov-19-20 06:00PM  
07:21AM  
07:00AM  
Nov-18-20 06:00PM  
12:16PM  
Nov-17-20 10:11AM  
08:21AM  
07:00AM  
Nov-16-20 11:28AM  
10:13AM  
Nov-13-20 07:00AM  
Nov-12-20 07:00PM  
07:38AM  
07:00AM  
06:45AM  
Nov-11-20 10:14AM  
Nov-05-20 07:00AM  
Nov-04-20 10:30AM  
Oct-26-20 09:00AM  
Oct-15-20 10:26AM  
Oct-14-20 11:00AM  
Oct-13-20 11:24AM  
10:30AM  
Oct-08-20 10:30AM  
Oct-07-20 10:00AM  
Oct-06-20 07:00AM  
Sep-23-20 02:31PM  
12:46PM  
10:35AM  
10:25AM  
06:46AM  
Sep-22-20 10:00AM  
Sep-09-20 07:00AM  
Sep-08-20 08:30AM  
Sep-03-20 07:05AM  
Aug-31-20 05:00PM  
Aug-27-20 07:00AM  
Aug-13-20 07:00PM  
07:17AM  
07:00AM  
06:10AM  
Aug-11-20 07:00PM  
Aug-07-20 11:25AM  
Aug-06-20 07:00AM  
Aug-05-20 07:00AM  
Aug-03-20 01:51PM  
07:00AM  
Jul-31-20 07:00AM  
Jul-30-20 07:00AM  
Jul-28-20 09:35AM  
Jul-27-20 07:00AM  
Jul-22-20 07:00AM  
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.